Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients

Autor: Xuedong Shen, Jianjun Zhang, Zhiqing Qiao, Qi Zhuang, Ying Zheng, Jieyan Shen, Xueming Zhang, Jian Li
Rok vydání: 2018
Předmět:
Liver Cirrhosis
Male
medicine.medical_treatment
Kaplan-Meier Estimate
030204 cardiovascular system & hematology
Liver transplantation
Gastroenterology
Liver disease
0302 clinical medicine
Risk Factors
Cause of Death
Prevalence
Cause of death
Portopulmonary hypertension
Liver Neoplasms
Middle Aged
Prognosis
Survival Rate
surgical procedures
operative
Echocardiography
Portal hypertension
Female
030211 gastroenterology & hepatology
Research Article
Adult
Pulmonary and Respiratory Medicine
China
medicine.medical_specialty
Carcinoma
Hepatocellular
Article Subject
Hypertension
Pulmonary
Diseases of the respiratory system
03 medical and health sciences
Hepatitis B
Chronic
Internal medicine
Hypertension
Portal
medicine
Humans
Mortality
Survival rate
Survival analysis
Retrospective Studies
RC705-779
business.industry
Pneumonia
medicine.disease
Pulmonary hypertension
Liver Transplantation
Logistic Models
Multivariate Analysis
business
Liver Failure
Zdroj: Canadian Respiratory Journal
Canadian Respiratory Journal, Vol 2018 (2018)
ISSN: 1916-7245
1198-2241
Popis: Objective. To investigate the prevalence and prognosis of portopulmonary hypertension (PoPH) in liver transplant recipients. Methods. Patients with advanced liver disease who underwent orthotopic liver transplantation (OLT) were included in this retrospective study from January 2012 to June 2015. According to the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for the diagnosis of pulmonary hypertension (PH), patients with tricuspid regurgitation velocity (TRV) >3.4 m/s or 2.9 m/s ≤ TRV ≤ 3.4 m/s coexisting with other echocardiographic PH signs were judged as PH. PH patients with portal hypertension and without other known causes of PH were diagnosed as PoPH. Results. A total of 223 (170 males and 53 females) middle-aged (50.9 ± 9 years old) liver transplant recipients were included in this study. Fourteen patients (6.3%) were diagnosed with PoPH, and none of the patients were treated with vasodilators before or after OLT. After OLT, patients were followed up for 26 ± 13.5 months. In total, 8 of 14 (57%) PoPH patients died, and the main cause of death was pulmonary infection. Kaplan–Meier survival curves revealed a significant difference in survival between PoPH and non-PoPH patients (p<0.001), and the median survival time after OLT of PoPH was 11.4 months. Conclusions. The prevalence of PoPH was 6.3% in OLT recipients. The survival of untreated PoPH patients was dismal after OLT.
Databáze: OpenAIRE
Externí odkaz: